Table 4

HER-2/neu gene status and clinicopathological and outcome variables

Amplified (%)Polysomic (%)Remaining cohort (%)
Total4 (100)5 (100)47 (100)
T stage
 1–21 (25)3 (60)15 (32)
 3–43 (75)2 (40)32 (68)
N stage
 001 (20)9 (19)
 11 (25)2 (40)21 (45)
 2–33 (75)2 (40)17 (36)
AJCCa stage
 II01 (20)4 (9)
 III02 (40)14 (30)
 IV4 (100)2 (40)29 (62)
Overall survival (%)
 5 yr04043
 10 yr04028
Mean survival time (yr)2.23.15.8
  • a AJCC, American Joint Committee on Cancer.